Skip to main content

Advertisement

Table 2 Drug treatment and morbidity at 6 and 12 months

From: Feasibility of evidence-based diagnosis and management of heart failure in older people in care: a pilot randomised controlled trial

  Control nA=11 Intervention nB= 14 P value (A-B)
6 months Use at optimum dose    
ACEi + β blocker 0 (0%) 3 (21%) 0.250
ACEi 3 (27%) 8 (57%) 0.414
Ramipril 2 (18%) 6 (43%) 0.402
β blocker 2 (18%) 3 (21%) 1.000
Bisoprolol 0 (0%) 3 (21%) 0.250
Spironolactone 0 (0%) 0 (0%) -
Use at any dose    
ACEi + β blocker 5 (45%) 10 (71%) 0.442
ACEi 5 (45%) 13 (93%) 0.075
Ramipril 4 (36%) 11 (79%) 0.122
β blocker 7 (64%) 12 (86%) 0.653
Bisoprolol 5 (45%) 11 (79%) 0.397
Spironolactone 0 (0%) 2 (14%) 0.500
Morbidity    
Hospitalisations at 6 months for HF 0 (0%) 0 (0%) -
Hospitalisations at 6 months for CVD 0 (0%) 0 (0%) -
Hospitalisations at 6 months for any cause 2 (18%) 1 (7%) 0.498
12 months (post-trial) Control n A = 8 Intervention n B = 13 P value (A-B)
Use at optimum dose    
ACEi + β blocker 0 (0%) 1 (8%) 1.000
ACEi 3 (38%) 5 (38%) 1.000
Ramipril 3 (38%) 4 (31%) 1.000
β blocker 0 (0%) 1 (8%) 1.000
Bisoprolol 0 (0%) 1 (8%) 1.000
Spironolactone 0 (0%) 0 (0%) -
Use at any dose    
ACEi + β blocker 5 (63%) 7 (54%) 1.000
ACEi 6 (75%) 11 (85%) 0.609
Ramipril 5 (63%) 10 (77%) 0.376
β blocker 5 (63%) 7 (54%) 1.000
Bisoprolol 5 (63%) 7 (54%) 1.000
Spironolactone 0 (0%) 2 (15%) 0.494
Morbidity    
Hospitalisations at 12months for HF 0 (0%) 0 (0%) -
Hospitalisations at 12 months for CVD 0 (0%) 0 (0%) -
Hospitalisations at 12 months for any cause 2 (25%) 3 (23%) 1.000